Juvent Names Chief Medical Advisor

Juvent, a developer of orthopedic regenerative therapies, has recruited Scott D. Boden, M.D., as its chief medical advisor. Boden is a tenured professor of orthopedic surgery at Emory University School of Medicine and serves as the director of the Emory Orthopeadics & Spine Center, vice chair of Orthopaedics, CMO/CQO of The Emory University Orthopaedics & Spine Hospital, and Emory Healthcare Physician Director of Strategy and Development for Orthopaedics & Spine Programs.
 
Boden has received numerous awards for his work and is the author of more than 175 peer-reviewed articles on spine and basic science topics; as well as 30 chapters and seven textbooks. He is co-editor of Seminars in Spine Surgery, a deputy editor of SPINE, and a reviewer for the Journal of Bone and Joint Surgery, the Journal of Bone and Mineral Research, and the European Spine Journal.
 
“Dr. Boden brings in-depth experience and perspective to our group and has a unique blend of medicine, science, and business skills,” said Rush Simonson, chairman and CEO of Regenerative Technologies Corporation. “His reputation and expertise will help us in our quest to expand the clinical value of the Juvent technology.”
 
In 2013, Boden served as president of the American Orthopaedic Association. He received his bachelor’s and medical degrees from the University of Pennsylvania and completed an orthopedic residency at The George Washington University Medical Center, followed by a Spine Fellowship at Case Western Reserve University Hospitals.
 
Additionally, Boden, Emory Orthopaedics and Spine are also pioneering a sports team and academic health-care partnership with the Atlanta Hawks and P3 (Peak Performance Project) in a soon-to-open 90,000-square foot, $50 million-dollar facility. Juvent is playing an ever-increasing role in professional sports as its device helps to rehabilitate athletes and speed recovery time after training. Olympic gold medal tennis champion Mike Bryan uses Juvent daily as well as many other national football players, such as Eric Wood Center with the Buffalo Bills.
 
Juvent’s presence in physical therapy centers continues to grow with one leading therapy franchise putting more than 80 percent of its patients on Juvent at each visit. “Dr. Boden’s experience and expertise in bone health is widely recognized and he will help drive Juvent’s product development and clinical applications,” said Juvent President Peter Simonson.
 
“We are just before entering our next round of funding to complete development and production of a low-cost consumer unit to meet the demand of a broader consumer market. Over 50 million people who suffer from osteoarthritis in the U.S. could benefit from this safe, non-invasive technology,” said Simonson.
 
Juvent’s Micro-Impact Platform is registered as a U.S. Food and Drug Administration Class I medical exercise and rehabilitation device. Juvent uses a unique, patented resonant wave technology to deliver thousands of low-magnitude and high-frequency micro-impacts that enter through the heels of the feet and move up the entire body. These micro-impacts safely stimulate the body’s muscles and bones to rebuild. Users stand on the Juvent for as little as 10 minutes per day and many begin to feel joint pain relief within days. Juvent’s platform is recommended and used by world-renowned trainers, doctors, physical therapists, and chiropractors. Juvent holds over 26 patents worldwide on its technology.
 
Juvent’s platform is also used in the athletic world for recovery and healing by leading organizations such as The David Leadbetter Golf Academy, NFL Alumni Association (NFLA), and Hospital for Special Surgery’s Pete Draovitch, PT, MS, ATC, CSCS. Some of the champion athletes using Juvent in their daily training regimens include Olympic tennis champion Mike Bryan, former NFL legend Ray Lewis, Eric Wood, and tennis legend Mats Wilander.
 
Juvent is a corporate advisory roundtable member of the National Osteoporosis Foundation (NOF).
 
Juvent is a part of Regenerative Technologies Corporation, a privately held, Florida company that manufactures the Juvent Micro-Impact Platform in the United States. The platform provides non-invasive, micro-impact pulses to support bone health, lymphatic drainage, relieve joint and back pain, and enhance balance. The Class I medical exercise and rehabilitation device is the result of more than 20 years and $45 million in research and development, with many peer-reviewed journals articles and six human clinical studies (completed or current) with backing from the National Institutes of Health, NASA, and the U.S. Army.